Back in 2023
The 8th annual Microbiome Connect: USA will return in November 2023, showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis.
At Microbiome Connect you will hear from microbiome biotechs, pharma voices, investment bodies, and more on how to develop robust, scalable, and reproducible formulations for microbe-derived/-targeting products entering late-stage investigations and reaching for the market.
Be sure to register your interest to be the first to receive the latest updates and news from the series!
HEAR FROM OUR COMMUNITY
Ahead of your visit to Microbiome Connect, hear from some of our partners and attendees on why the series is a must-attend for them - and why you can't miss 2023!
Microbiome Connect has evolved into a "not to miss" event. The opportunity to hear the latest developments across a wide range of companies and key academic/regulatory groups is unique. Additionally, the networking opportunities are second to none. I intend to return.
A great platform to discuss the currently most relevant microbiome topics - a must for microbiome drug developers.
This event was full of brilliant individuals dedicated to the field. It was both inspiring and exciting!
Microbiome Connect USA 2022 was a great opportunity to meet with, learn from and exchange with all stakeholders committed to advancing microbiome therapies and diagnostics.
This event was a great way to get up to date on where the field is and on where it wants to go. Both technology and R&D companies were represented, which was very useful. I appreciated having the two tracks of talks to choose from too.
Fascinating research, stimulating variety of speakers and topics in the field of the Human Microbiome & Therapeutics. The app made the conference easy to navigate, plan and make connections.
Informative sessions, Networking opportunities, Biotech pitch and discussing current and future challenges and opportunities in this emerging space with industry leaders was phenomenal!
If being part of the Microbiome Therapeutics conversation is important to your research or business goals, this is the place to be.
This was an intimate meeting with an excellent focus and presentations on the current state of Microbiome therapies and future prospects in the field.
EVENT SCHEDULE
Register your interest and be the first to see the full line-up of speakers sessions and discussions taking place at Microbiome Connect: USA 2023!
BE THE FIRST TO SEE THE AGENDA
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
2022 SPEAKER FACULTY
Peter Marks
Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.
Vanessa Ridaura
Thomas Gurry
Nini Fan
Vivek Lal
Benjamin Hadida
Sandrine Miller-Montgomery
Stewart Campbell
Dr. Campbell joined Axial in 2016 as Vice President of Research & Development, and was appointed the company’s CEO in February 2021. in 27+ years in the pharma/biotech industry, Dr. Campbell held various leadership roles at Boehringer-Ingelheim, Insmed, Surface Logix, Ancora/Corden Pharma and Axial, Dr. Campbell has played an integral role in the discovery and development of eight clinical stage drug candidates, including the Rho kinase inhibitor belumosudil and TAK-607 (rIGF-1/BP-3). During his career Dr. Campbell has been co-inventor on 20 issued patents. He holds a BSc with Honors in Chemistry from St. Francis Xavier University, a Ph.D. in Organic Chemistry from the Queen’s University (Canada), and did post-doctoral research at Duke University.
Shrish Budree
Koji Yasuda
Todd Krueger
Leigh A. Frame, PHD, MHS
Scott Jackson
Paul Carlson
Sabine Hazan
Dr Elran Haber
Fabio Grassi
Sou Miyake
Georg Gerber K.,M.,D.,Ph.D.,M.P.H.,
Katie Leitch
Bharat Dixit
Denise Kelly
Naveen Krishnan
Diwikar Davar
Romain Daillere
Larry Weiss
Cheri Ackerman
Trevor Steyn
Dan Couto
Ron Shmueli
Nikhil Sharma
Chris Ford
Anik Debanth
Johan E.T. van Hylckama Vlieg
Peter Lee MD
Marina Santiago
Sheng-Lin Gibson
Staffan Stromberg
Zack Abbott
Jason Norman
Nikole Kimes
Felix Faupel
Stacy Burns Gurdish
Joe Trebley
Tomas De Wouters
Manoj Dadlani
Mary Poor
Tonya Ward
Kit Goldman
Ryan Wilson
Nicolas Pichon
MEET OUR COMMUNITY
OUR 2023 SPONSORS & PARTNERS
Platinum Partner
CosmosID
Website: www.cosmosid.com
CosmosID® provides end-to-end solutions unlocking the microbiome. A provider of CLIA-certified & ICH-GCP compliant NGS Services and Bioinformatics Solutions, CosmosID offers a range of validated and optimized workflows for research and development.
CosmosID also offers independently validated, industry-leading pipelines for processing metagenomic data, yielding multi-kingdom, strain-level resolution with leading sensitivity and precision. Results can be accessed via CosmosID-HUB, a user-friendly and interactive software for comparative analysis of microbiome data, complete with dynamic charts, visualizations, and statistics.
Gold Partners
ReciBioPharm
Website: https://www.recipharm.com/about-us/bolstering-biologics
Please visit our website for more information.Biose Industrie
Website: https://www.biose.com/
Biose Industrie is a Contract Development and Manufacturing Organization (CDMO), specialised in Live Biotherapeutic Products. Founded in 1951, Biose Industrie has more than 65 years of experience in the development and production of live bacteria based drugs. Company offers lab development specialised in microbiology (anaerobic, aerobic, GMO strains) and is Drug GMP certified for the manufacturing of API (From 300L to 3 500L), clinical batches and commercial drug products (capsules in blisters or pills, sachets).
Bacthera
Website: https://www.bacthera.com/
Bacthera is a Danish/Swiss-based one-stop CDMO in the field of LBP’s, with the overall goal to enable the entire industry to further flourish by introducing industry changing innovations.
From small start-up’s to globally operating pharmaceutical companies, we support our clients developing analytical and manufacturing processes of their strains. With our long experience in handling bacteria in DS and DP production, we can offer tailor-made development and large-scale commercial solutions. Within our facilities, we can handle:
- Strictly and facultative anaerobes
- BSL1/2 categorized strains
- GMO’s
Our customers benefit from background technologies and GMP manufacturing know-how that originate from our mother companies Chr. Hansen & Lonza. In addition, Bacthera’s process expertise, enabling innovations and our world-class analytical services will contribute to our customer’s successful development of their LBP.
Quay Pharma
Website: https://www.quaypharma.com
Quay are world known experts in formulation development and clinical manufacturing of live biotherapeutic dosage forms.
No other CDMO has the breadth of knowledge in the formulation services we offer, our clinical trials manufacturing and supply know how as well as our specialist knowledge in providing cost efficient engineering solutions to meet the many challenges that we know can accompany the finished product manufacture of microbial therapies.
Twenty years of focused know how on formulation and analytical development to meet the demands of global regulatory authorities at all clinical phases, has established Quay Pharma as a leading innovator in the fast growing microbial therapies space. We work with bacteria including fastidious anaerobes, multi-species consortia, viruses including bacteriophages and viral vectors and microbially derived drug products such as recombinant peptides and spores. This diversity requires a broad range of expertise, analytical techniques, operational flexibility and handling requirements to ensure safe and efficacious manufacture specifically during manufacturing scaleup for clinical supply.
We are fully licensed for handling BS class 1 and 2 strains as well genetically modified microorganisms. Quay is able to support your GMP manufacture in Europe and is extending this capability to its new facility in the US.
Unlike other CDMO’s Quay offers a specific formulation route that meets your target profile requirements. We know, from experience, that off the shelf solutions, such as intrinsically enteric capsules do not always work and certainly can not provide the protection to your therapeutics potency that other formulation options do.
Get in touch, we look forward to discussing a bespoke solution to meet your therapeutic needs.
Event Partner
Track Partner
JAFRAL
Website: https://jafral.com/
JAFARAL is world’s leading CMO for production of bacteriophages, because it’s has more than 10 years’ experience in manufacturing of phages, other biologics production, large scale production and knowing GMP guidelines. Likewise, JAFRAL has all these years also been involved in plasmid DNA and recombinant proteins production at various levels. JAFRAL’s custom development and manufacturing services have helped developers across the globe to accelerate research and open up their laboratories for ground-breaking science and breakthrough discoveries.
Venue
HYATT REGENCY BOSTON ONE AVENUE DE LAFAYETTE BOSTON, MA, 02111, US
Microbiome Connect invites you to join us at the Hyatt Regency Boston on the November 15-16, 2023.
Discounted rooms available to attendees here.
Partner with Us
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact [email protected]
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.